# IRIDEX CORP (IRIX) · Edgar & Edgarette company card

> Iridex (IRIX) grew revenue 8.2% in FY2026 to $53 million, operating margin -4.9% against a 7.5% median for electromedical & electrotherapeutic apparatus, equity 16.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1006045 · fiscal year ended 2026-01-03 · 5 audited years read · [page](https://www.pops4.com/boards/company/IRIX) · [JSON](https://www.pops4.com/boards/company/IRIX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $53M |
| Revenue growth, 1 year | 8.2% |
| Revenue growth per year | -0.6% |
| Operating margin | -4.9% (prior year -17.1%) |
| Net margin | -8.4% |
| Operating cash flow | −$2M |
| Capital spending | $143,000 |
| Free cash flow | −$2M |
| Cash | $6M |
| Long-term debt | — |
| Total assets | $29M |
| Total equity | $5M |
| Equity ÷ assets | 16.9% |
| Return on equity | -90.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -8.01 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -2.56 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -4.9% in FY2026; revenue is hard to predict: its 80% range is ±39%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $52.7M (FY2026). Experience: revenue up 8.2% on the year, down 0.6% a year over 4 years; operating margin -4.9%, up from -17.1%. Soundness: equity 16.9% of assets, return on equity -90.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $34.5M and $79.4M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $35.6M to $77.1M. A statistical range, not company guidance. Against peers (13 filers, $50M+ revenue, electromedical & electrotherapeutic apparatus): operating margin -4.9% against a 7.5% median; growth 8.2% against 8.3%.

Range logged 2026-09-29, receipt 928eeee0bf229fcd, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-09-02 ([filing](https://www.sec.gov/Archives/edgar/data/1006045/000119312526380229/0001193125-26-380229-index.htm))

## Recent filings

- 8-K · filed 2026-09-02 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1006045/000119312526380229/0001193125-26-380229-index.htm)
- 10-Q · filed 2026-08-18 · [filing](https://www.sec.gov/Archives/edgar/data/1006045/000119312526355641/0001193125-26-355641-index.htm)
- 8-K · filed 2026-08-18 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1006045/000119312526355635/0001193125-26-355635-index.htm)
- 8-K · filed 2026-07-16 · 5.07 Submission of Matters to a Vote of Security Holders; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1006045/000119312526305344/0001193125-26-305344-index.htm)
- 8-K · filed 2026-06-18 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1006045/000119312526275883/0001193125-26-275883-index.htm)
- 10-Q · filed 2026-05-19 · [filing](https://www.sec.gov/Archives/edgar/data/1006045/000119312526230789/0001193125-26-230789-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001006045.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1006045

## Cite

POPS4, Edgar & Edgarette: IRIDEX CORP (IRIX) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/IRIX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.